21 Novembner 2019 (Thursday) - Oncologist Newsletter

“The Oncologist” newsletter appeared in my in-box this morning. You can read it here. I did…

As always, it is full of stuff about how such-and—such is treated, the outcomes of clinical trials, the latest drugs. Very little on how the white cell morphology varies in such-and-such, the affects of clinical trials on the specifics of blood parameters, or how the latest drugs specifically affect the blood count.

But it is useful background reading, it doesn’t cost me a penny, and I am grateful for it…

21 November 2019 (Thursday) - BTLP-TACT Excercise

Despite it being less than two weeks since I last did a BTLP-TACT exercise, I got a reminder to do one…

So I did one.

I was presented with one case; a twenty-seven year old woman with spontaneous rupture of membranes who needed a group and save.

She grouped as AB Rh(D) Negative with a negative antibody screen

I got the green light

 

18 November 2019 (Monday) - ASH Update

The American Society of Hematology’s update arrived today. It focussed on haemostasis:

	Heparin-Induced Thrombocytopenia Does Not Appear to Protect Against Major Bleeding Results published in the Journal of Thrombosis and Haemostasis suggest no difference in bleeding risk between people with suspected HIT and those without.
	Older Patients with iTTP Have Delayed Diagnosis and Higher Mortality Than Younger Counterparts The atypical presentation of immune thrombotic thrombocytopenic purpura in older adults can lead to delays in diagnosis, contributing to their worse prognosis.
	Breakthroughs for Bleeding: Updates in Treating and Managing Hemophilia Experts review the new therapies in clinical use and in development for patients with hemophilia, from extended half-life recombinant factor products to RNA interference therapies.